<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02608177</url>
  </required_header>
  <id_info>
    <org_study_id>50084-A</org_study_id>
    <nct_id>NCT02608177</nct_id>
  </id_info>
  <brief_title>Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management</brief_title>
  <acronym>CANDY-CANE</acronym>
  <official_title>Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to test whether a dipeptidyl peptidase-4 inhibitor, compared with a
      sulfonylurea, improves time in normal blood glucose range and reduces blood glucose
      variability. Blood glucose is measured using a continuous glucose monitoring device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a proof-of-concept clinical trial testing the effects of linagliptin versus glipizide
      on glucose variability among people with type 2 diabetes and stage 3-4 CKD. In a cross-over
      design, each enrolled participant will receive 28 days of each study medication. Study
      medications will be provided in a randomly assigned order without blinding. The primary study
      outcome is glucose time in range, measured by blinded continuous glucose monitoring for the
      last 6 days of each 28-day treatment period. Secondary outcomes include indices of glycemic
      variability, hypoglycemia, and biomarkers of systemic inflammation, oxidative stress, and
      albuminuria. The overall goal of this research is to identify safe and effective treatments
      to control glycemia among patients with diabetes and CKD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose time in range</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemic variability</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of systemic inflammation</measure>
    <time_frame>28 days</time_frame>
    <description>Measured by plasma C-reactive protein (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of systemic inflammation</measure>
    <time_frame>28 days</time_frame>
    <description>Measured by plasma interleukin-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of oxidative stress</measure>
    <time_frame>28 days</time_frame>
    <description>Measured by plasma F2-isoprostanes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of oxidative stress</measure>
    <time_frame>28 days</time_frame>
    <description>Measured by urine F2-isoprostanes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of albuminuria</measure>
    <time_frame>28 days</time_frame>
    <description>Measured by albumin-creatinine ratio</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Linagliptin/Glipizide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm receives 4 weeks of study drug linagliptin followed by 4 weeks of glipizide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glipizide/Linagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm receives 4 weeks of study drug glipizide followed by 4 weeks linagliptin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>Receives 4 weeks of study drug linagliptin</description>
    <arm_group_label>Linagliptin/Glipizide</arm_group_label>
    <arm_group_label>Glipizide/Linagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glipizide</intervention_name>
    <description>Receives 4 weeks of study drug glipizide</description>
    <arm_group_label>Linagliptin/Glipizide</arm_group_label>
    <arm_group_label>Glipizide/Linagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  eGFR 15-59 mL/min/1.73 m2

          -  Hemoglobin A1c &lt; 8%

          -  Age â‰¥ 18 years

          -  Current use of sulfonylurea

        Exclusion Criteria:

          -  BMI &gt; 40 kg/m2

          -  Actively using CGM for clinical care

          -  End stage renal disease needing dialysis

          -  Kidney transplant

          -  Pregnant or nursing

          -  Unable to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian de Boer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Curtin</last_name>
    <phone>(206) 221-3938</phone>
    <email>lcurtin@uw.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Connor Henry</last_name>
    <email>chenry@uw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Curtin</last_name>
      <phone>206-221-3938</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2015</study_first_submitted>
  <study_first_submitted_qc>November 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2015</study_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Ian deBoer</investigator_full_name>
    <investigator_title>Associate Professor, Medicine/Nephrology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
    <mesh_term>Glipizide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

